MDGL — Madrigal Pharmaceuticals Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $421.99
- YTD price return
- -27.54%
- YTD total return
- -27.54%
- Market cap
- 9.8B
- Enterprise value
- 9B
- Shares outstanding
- 23.2M
- 52W low
- $353.54
- 52W high
- $615.00
- From 52W high
- -31.38%
- From 52W low
- +19.36%
- 52W range
- 26%$354–$615
- Beta
- -0.97
Volume
- Rel volume
- 0.72×
- 30D volume
- 506.5K
- 30D $ vol
- 215.7M
Insider trading
- Insider net 1W
- none
- Insider net 1M
- +$34.6M
- Insider net 3M
- +$28.4M
- Insider net 1Y
- −$5.6M
Form 4 transactions by trade date, as filed; latest on file 2026-11-06.
Fundamentals
- Sales (ttm)
- 1.4B
- Sales/share
- $61.47
- EPS (ttm)
- -$5.13
- FCF (ttm)
- -168.7M
- FCF/share
- -$7.26
- Book value/share
- $26.99
- Net margin
- -10.89%
- ROE
- -24.80%
- ROA
- -10.84%
- Debt / equity
- 0.54×
- Current ratio
- 3.05
Growth (CAGR, ttm) · 10Y
- Sales
- +92.88%n/an/an/a
- Shares
- +2.28%+5.57%+6.32%+7.22%
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +88.58%n/an/an/a
- Book value/share
- -2.04%+188.17%+14.46%+23.58%
- Price
- -23.76%+33.67%+37.16%+38.07%
- Total return
- -23.76%+33.67%+37.16%+38.07%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -82.3×
- Fwd P/E
- 37.6×
- P/S (ttm)
- 6.9×
- P/B (mrq)
- 15.6×
- EV/Sales (ttm)
- 6.3×
- FCF yield (ttm)
- -1.72%
- Buyback yield (realized, 1y)
- -2.28%
- Shareholder yield (realized, 1y)
- -2.28%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/B
- 75th
Bar = where today’s multiple sits in MDGL’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-17#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m10Y n/mYoY n/mEPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y n/m10Y n/mYoY +47.6%TTM: operating cash flow −$157M, capex −$11.6M
Q3 2026: operating cash flow $120.6M, capex −$3.9M
Shares (diluted)
5Y +45.2%5Y +45.2%YoY +6.3%Net income
5Y n/m10Y n/mYoY n/mAbout Madrigal Pharmaceuticals#
Data provided bySource: Twelve DataMadrigal Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with significant unmet medical need. Its lead product, Rezdiffra, is a once-daily oral therapy designed to address the underlying biology of MASH in adults with moderate to advanced liver fibrosis. The company’s current business is centered on liver disease, with a commercial presence supported by medical affairs, patient support, and market access activities. Madrigal Pharmaceuticals Inc. also maintains research and clinical development efforts around thyroid hormone receptor-beta science, reinforcing its role as a specialist company in hepatology and metabolic medicine. Based in West Conshohocken, Pennsylvania, Madrigal Pharmaceuticals Inc. serves a focused segment of the biopharmaceutical market that targets chronic liver and metabolic disorders.
West Conshohocken, PA·915 employees·Biotechnology·madrigalpharma.com·As of Oct 28, 2026
Recent filings#
- Nov 6Insider buy · BAKER BROS. ADVISORS LP, Baker Bros. Advisors (GP) LLC, BAKER FELIX, BAKER JULIAN, 667, L.P., Baker Brothers Life Sciences LP (6 filers) bought 91,806 shares for $35.0M on 2 days since Nov 4
- Nov 3Earnings · Earnings release — EPS $1.83 vs −$1.09 est. (+267.9%); revenue $431.3M (+50% y/y) 8.1%
- Aug 17Insider sale · Kelley Shannon T (General Counsel) sold 664 shares for $342K at $514.97
- Aug 128-K · Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
- Jul 30Earnings · Earnings release — EPS −$1.99 vs −$2.55 est. (+22.0%); revenue $364.3M (+71% y/y) 9.8%
ETFs holding MDGL#
19 of the 193 ETFs ChartRow carries live hold MDGL. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| XBI | SPDR S&P Biotech ETF | 1.1% |
| IBB | iShares Biotechnology ETF | 0.9% |
| VBK | Vanguard Small-Cap Growth ETF | 0.3% |
| IWP | iShares Russell Mid-Cap Growth ETF | 0.3% |
| VB | Vanguard Small-Cap ETF | 0.1% |
| VXF | Vanguard Extended Market ETF | 0.1% |
| VHT | Vanguard Health Care ETF | 0.1% |
| IWR | iShares Russell Midcap ETF | 0.1% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +12.61% | -1.13% |
| JNJ | Johnson & Johnson | +9.05% | -1.36% |
| ABBV | AbbVie Inc. | +2.59% | -0.59% |
| MRK | Merck & Co. Inc. | -1.77% | -0.75% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -2.93% | -5.42% |
| NVS | Novartis AG | +5.65% | -0.67% |
| TMO | Thermo Fisher Scientific Inc. | -0.47% | -0.66% |
| AMGN | Amgen Inc. | +5.88% | -0.95% |
